Genelux Corporation Common Stock reports a Return on Equity (ROE) of -138.64%.

What is GNLX's dividend yield?

Genelux Corporation Common Stock offers a dividend yield of 0.00%.

What is GNLX's Quality Score?

Our AI rates GNLX's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy GNLX?

Our AI Timing Score for GNLX is 69 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does GNLX belong to?

Genelux Corporation Common Stock is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Genelux Corporation (GNLX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

GNLX AI Analysis Summary

Our AI summary for GNLX: Genelux Corporation Common Stock (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -138.64%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 69/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

GNLX

Genelux Corporation Common Stock

US:NASDAQ STOCK Healthcare >> Biotechnology News 70

USD 2.82

-0.16 (-5.37%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-138.6%

ROE

-98.2%

ROA

0.00%

Div Yield

GENELUX CORPORATION COMMON STOCK
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.82 Price -0.16 (-5.37%) Day Change	NEWS SCORE: 70

GNLX, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

42%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	70
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.82
PBV / Sector	5.83 / 44,022.72
Earning Per Share	-0.67

PE / Sector	N/A / 19.17
PEG or PE/Growth / Sector	N/A / 1.24
Average 1M Daily Value	0.57 M GREAT
Average 1W Daily Value	1.01 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-397,225.00 / 98.24
NPM Average (%) / Sector	-237,818.47 / -1,697.63
NPM Change Average (%) / Sector	9,357.69 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-98.17 / 185,260.96
ROA Average (%) / Sector	-109.75 / 36,684.70
ROA Change Average (%) / Sector	11.76 / 422,221.66 GOOD
ROE (%) / Sector	-138.64 / 243,762.23
ROE Average (%) / Sector	-132.31 / 48,758.47
ROE Change Average (%) / Sector	-256.41 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:00:16
Symbol	GNLX
Name	GENELUX CORPORATION COMMON STOCK
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	44.84 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	133.62 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2625 Townsgate Road, Westlake Village, CA, United States, 91361

Phone: 805 267 9889

Website: https://www.genelux.com

Sector: Healthcare >> Biotechnology

Description: Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.